Bcl6 promotes osteoblastogenesis through stat1 inhibition

Biochemical and Biophysical Research Communications

Volumn 457, Issue 3, 2015, Pages 451-456

  Fujie, Atsuhiro ^a   Funayama, Atsushi ^a   Miyauchi, Yoshiteru ^a   Sato, Yuiko ^a   Kobayashi, Tami ^a   Kanagawa, Hiroya ^a   Katsuyama, Eri ^a   Hao, Wu ^a   Tando, Toshimi ^a   Watanabe, Ryuichi ^a   Morita, Mayu ^a   Miyamoto, Kana ^a   Kanaji, Arihiko ^a   Morioka, Hideo ^a   Matsumoto, Morio ^a   Toyama, Yoshiaki ^a   Miyamoto, Takeshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bcl6; Bone; Differentiation; Osteoblast; Stat1

Indexed keywords

MESSENGER RNA; PROTEIN BCL 6; STAT1 PROTEIN; TRANSCRIPTION FACTOR RUNX2; BCL6 PROTEIN, MOUSE; DNA; DNA BINDING PROTEIN; STAT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE MASS; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELLS BY BODY ANATOMY; CELLULAR PARAMETERS; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLASTOGENESIS; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; WILD TYPE; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; BONE DEVELOPMENT; BONE REMODELING; C57BL MOUSE; CYTOLOGY; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; OSTEOBLAST; PHYSIOLOGY; PROMOTER REGION;

MUS;

3T3 CELLS; ANIMALS; BINDING SITES; BONE REMODELING; CELL DIFFERENTIATION; DNA; DNA-BINDING PROTEINS; FEMALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; STAT1 TRANSCRIPTION FACTOR;

EID: 84922738990     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.01.012     Document Type: Article

References (30)

1. T. Komori, H. Yagi, S. Nomura, et al., Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts, Cell 89 (5) (1997) 755-764.
2. P. Ducy, R. Zhang, V. Geoffroy, et al., Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation, Cell 89 (5) (1997) 747-754.
3. K. Nakashima, X. Zhou, G. Kunkei, et al., The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation, Cell. 108 (1) (2002) 17-29.
4. H. Takayanagi, S. Kim, T. Koga, et al., Induction and activation of the transcription factor NFATc1(NFATc2) integrate RANKL signaling in terminal differentiation of osteoclasts, Dev. Cell 3 (2002) 889-901.
5. A.E. Grigoriadis, Z.Q. Wang, M.G. Cecchini, et al., c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling, Science 266 (5184) (1994) 443-448.
6. K. Matsuo, D.L. Galson, C. Zhao, et al., Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos, J. Biochem. 279 (25) (2004) 26475-26480.
7. C. Bastard, H. Tilly, B. Lenormand, et al., Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma, Blood 79 (1992) 2527-2531.
8. H. Ohno, Pathogenetic and clinical implications of non-immunoglobulin; Bcl6 translocations in B-cell non-Hodgkin's lymphoma, J. Clin. Exp. Hematop. 46 (2) (2006) 43-53.
9. Y. Miyauchi, K. Ninomiya, H. Miyamoto, et al., The Blimp1-Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis, J. Exp. Med. 207 (4) (2010) 751-762.
10. S. Kim, T. Koga, M. Isobe, et al., Stat1 functions as cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation, Genes Dev. 17 (16) (2003) 1979-1991.
11. M. Hayashi, T. Nakashima, M. Taniguchi, et al., Osteoprotection by semaphoring 3A, Nature 485 (7396) (2012) 69-74.
12. R. Kiviranta, K. Yamana, H. Saito, et al., Coordinated transcriptional regulation of bone homeostasis by Ebf1 and Zfp521 in both mesenchymal and hematopietic lineages, J. Exp. Med. 210 (5) (2013) 969-985.
13. M. Yagi, T. Miyamoto, Y. Sawatani, et al., DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells, J. Exp. Med. 202 (3) (2005) 34-51.
14. S.H. Lee, J. Rho, D. Jeong, et al., v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation, Nat. Med. 12 (12) (2006) 1403-1409.
15. T. Fukuda, T. Yoshida, S. Okada, et al., Disruption of Bcl6 gene results in an impaired germinal center formation, J. Exp. Med. 186 (3) (1997) 439-448.
16. M.A. Meraz, J.M. White, K.C.F. Sheehan, et al., Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway, Cell 84 (3) (1996) 431-442.
17. Y. Miyauchi, Y. Sato, T. Kobayashi, et al., HIF1α is required for osteoclast activation by estrogen de ficiency in postmenopausal osteoporosis, Proc. Natl. Acad. Sci. U. S. A. 110 (41) (2013) 16568-16573.
18. J.M. Polo, P. Juszczynski, S. Monti, et al., Transcriptional signature with differential expression of Bcl6 target genes accurately identifies Bcl6-dependent diffuse large B cell lymphomas, Proc. Natl. Acad. Sci. U. S. A. 104 (9) (2007) 3207-3212.
19. C.H. Heldin, K. Miyazono, P. Dijke, TGF-β signaling from cell membrane to nucleus through SMAD proteins, Nature 390 (6659) (1997) 465-471.
20. Y. Yoshida, S. Tanaka, H. Umemori, et al., Negative regulation of BMP/Smad signaling by Tob in osteoblasts, Cell. 103 (7) (2000) 1085-1097.
21. H. Takayanagi, S. Kim, T. Koga, et al., Stat1-mediated cytoplasmic attenuation in osteoimmunology, J. Cell. Biochem. 94 (2) (2005) 232-240.
22. E.A. Wang, V. Rosen, J.S. D'alessandro, et al., Recombinant human bone morphogenetic protein induces bone formation, Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 2220-2224.
23. E. Canalis, Wnt singaling in osteoporosis:mechanisms and novel therapeutic approaches, Nat. Rev. Endocrinol. 9 (10) (2013) 575-583.
24. E.M. Lewiecki, New targets for intervention in the treatment of postmenopausal osteoporosis, Nat. Rev. Rheumatol. 7 (11) (2011) 631-638.
25. H. Takayanagi, Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems, Nat. Rev. Immunol. 7 (4) (2007) 292-304.
26. S.L. Teitelbaum, F.P. Ross, Genetic regulation of osteoclast development and function, Nat. Rev. Genet. 4 (8) (2003) 638-649.
27. T. Hideshima, C. Mitsiades, H. Ikeda, et al., A proto-oncogene BCL6 is upregulated in the bone marrow microenvironment in multiple myeloma cells, Blood 115 (18) (2010) 3772-3775.
28. D.A. Frank, S. Mahajan, J. Ritz, Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling, Nat. Med. 5 (4) (1999) 444-447.
29. C.V. Obvina, J.E. Zerwekh, D.S. Rao, et al., Severely suppressed bone turnover: a potential complication of alendronate therapy, J. Clin. Endocrinol. Metab. 90 (3) (2005) 1294-1301.
30. G.A. Rodan, T.J. Martin, Therapeutic approaches to bone disease, Science 289 (5484) (2000) 1508-1514.